KCNH2 and malaria: Compound 1 displayed high in vitro antiplasmodium activity (PfNF54/K1 = 0.012/0.040μM) and demonstrated in vivo efficacy in a Plasmodiumberghei mouse malaria infectionmodel (P. berghei, 99% activity when administeredorally at 50 mg·kg–1 once daily for 4 days,with mouse survival of 14-days), and a relatively good pharmacokinetic(PK) profile.13 Despite its >1000-foldincrease in selectivity over hERG K+ channels comparedto AST, it still possesses a potential cardiotoxicity liability signaledby the high hERG inhibition activity (IC50 = 0.63 μM)and a low selectivity index (SI = 53).